Abstract
The replicative cycle of the human immunodeficiency virus (HIV) can be interrupted at several stages. Until recently only the viral reverse transcriptase and protease were the only enzymes targeted by antiretroviral agents. However, the first HIV entry inhibitor (T-20, Enfuvirtide, Fuseon) to be used in humans has been approved by the Food and Drug Administration (FDA). The HIV entry process is considered as an attractive target for chemotherapeutic intervention, as blocking HIV entry into its target cell leads to suppression of viral infectivity, replication and the cytotoxicity induced by virus-cell contacts. HIV-1 entry into target cells is a multistep process: virus attachment is initiated by the binding of trimeric envelope glycoprotein gp120 complexes on the virions to glycosylated T-cell surface receptor (CD4) and HIV GPCR coreceptors (CCR5 or CXCR4) leading to envelope glycoprotein gp41-dependent fusion-pore formation and membrane fusion. A number of compounds are being developed to specifically target each of these steps leading to virus entry and some compounds have reached early clinical development. Conversely, agents such as the CCR5 antagonist Tak-779 and the CXCR4 antagonist AMD3100 are not longer being thought as relevant anti-HIV agents but have given way to new analogues with improved properties. This review summarizes the current state of HIV entry inhibitors, their mechanisms of action and their therapeutic value against HIV infection and AIDS.
Keywords: hiv, aids, entry ihibitors, fusion, antivirals, drug development
Current Medicinal Chemistry
Title: Virus Entry as a Target for Anti-HIV Intervention
Volume: 10 Issue: 17
Author(s): Jose A. Este
Affiliation:
Keywords: hiv, aids, entry ihibitors, fusion, antivirals, drug development
Abstract: The replicative cycle of the human immunodeficiency virus (HIV) can be interrupted at several stages. Until recently only the viral reverse transcriptase and protease were the only enzymes targeted by antiretroviral agents. However, the first HIV entry inhibitor (T-20, Enfuvirtide, Fuseon) to be used in humans has been approved by the Food and Drug Administration (FDA). The HIV entry process is considered as an attractive target for chemotherapeutic intervention, as blocking HIV entry into its target cell leads to suppression of viral infectivity, replication and the cytotoxicity induced by virus-cell contacts. HIV-1 entry into target cells is a multistep process: virus attachment is initiated by the binding of trimeric envelope glycoprotein gp120 complexes on the virions to glycosylated T-cell surface receptor (CD4) and HIV GPCR coreceptors (CCR5 or CXCR4) leading to envelope glycoprotein gp41-dependent fusion-pore formation and membrane fusion. A number of compounds are being developed to specifically target each of these steps leading to virus entry and some compounds have reached early clinical development. Conversely, agents such as the CCR5 antagonist Tak-779 and the CXCR4 antagonist AMD3100 are not longer being thought as relevant anti-HIV agents but have given way to new analogues with improved properties. This review summarizes the current state of HIV entry inhibitors, their mechanisms of action and their therapeutic value against HIV infection and AIDS.
Export Options
About this article
Cite this article as:
Este A. Jose, Virus Entry as a Target for Anti-HIV Intervention, Current Medicinal Chemistry 2003; 10 (17) . https://dx.doi.org/10.2174/0929867033457098
DOI https://dx.doi.org/10.2174/0929867033457098 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Investigation Binding Patterns of Human Carboxylesterase I (hCES I) with Broad Substrates by MD Simulations
Current Topics in Medicinal Chemistry Diterpenoids from Liverworts and their Biological Activities
Current Organic Chemistry Benzothiazoles: How Relevant in Cancer Drug Design Strategy?
Anti-Cancer Agents in Medicinal Chemistry The WWW as a Tool to Obtain Molecular Parameters
Mini-Reviews in Medicinal Chemistry Magnetite Nanostructures with Applications in Cancer Therapy
Current Proteomics The Patient with a Single Cardiac Ventricle
Current Pediatric Reviews Integrated Genomic and Pharmacological Approaches to Identify Synthetic Lethal Genes as Cancer Therapeutic Targets
Current Molecular Medicine Aging of the Innate Immune System: An Update
Current Immunology Reviews (Discontinued) Targeting Sarcomas: Novel Biological Agents and Future Perspectives
Current Drug Targets Intervertebral Disc Engineering through Exploiting Mesenchymal Stem Cells: Progress and Perspective
Current Stem Cell Research & Therapy Advances in the Development of Inactivated Virus Vaccines
Recent Patents on Anti-Infective Drug Discovery Antibiotics’ Sustainability: Another Issue in the Fight against Antimicrobial Resistance
Current Topics in Medicinal Chemistry Artificial Intelligence in Pharmacovigilance and COVID-19
Current Drug Safety Glycomimetics at the Mirror: Medicinal Chemistry of L-Iminosugars
Current Medicinal Chemistry Prediction of Cell-Penetrating Peptides Using Artificial Neural Networks
Current Computer-Aided Drug Design Medicinal Chemistry of Small Molecule CCR5 Antagonists for Blocking HIV-1 Entry: A Review of Structural Evolution
Current Topics in Medicinal Chemistry Dynamic Crosstalk between GlcNAcylation and Phosphorylation: Roles in Signaling, Transcription and Human Disease
Current Signal Transduction Therapy Synthesis and Antitumour Activity of the Primin (2-methoxy-6-n-pentyl-1,4-benzoquinone) and Analogues
Medicinal Chemistry The Medicinal Potential of Influenza Virus Surface Proteins: Hemagglutinin and Neuraminidase
Current Medicinal Chemistry The Interaction Network of MicroRNAs with Cytokines and Signaling Pathways in Allergic Asthma
MicroRNA